129 related articles for article (PubMed ID: 33323405)
21. Oncogenic alterations in ERBB2/HER2 represent potential therapeutic targets across tumors from diverse anatomic sites of origin.
Chmielecki J; Ross JS; Wang K; Frampton GM; Palmer GA; Ali SM; Palma N; Morosini D; Miller VA; Yelensky R; Lipson D; Stephens PJ
Oncologist; 2015 Jan; 20(1):7-12. PubMed ID: 25480824
[TBL] [Abstract][Full Text] [Related]
22. Genomic characterization of Chinese ovarian clear cell carcinoma identifies driver genes by whole exome sequencing.
Yang Q; Zhang C; Ren Y; Yi H; Luo T; Xing F; Bai X; Cui L; Zhu L; Ouyang J; Jiang P; Fan W; Qiu J; Wang F; Xing X; Zhang Z; Zhang X; Zhang R
Neoplasia; 2020 Sep; 22(9):399-430. PubMed ID: 32650224
[TBL] [Abstract][Full Text] [Related]
23. Targeted DNA and RNA Sequencing of Paired Urothelial and Squamous Bladder Cancers Reveals Discordant Genomic and Transcriptomic Events and Unique Therapeutic Implications.
Hovelson DH; Udager AM; McDaniel AS; Grivas P; Palmbos P; Tamura S; Lazo de la Vega L; Palapattu G; Veeneman B; El-Sawy L; Sadis SE; Morgan TM; Montgomery JS; Weizer AZ; Day KC; Neamati N; Liebert M; Keller ET; Day ML; Mehra R; Tomlins SA
Eur Urol; 2018 Dec; 74(6):741-753. PubMed ID: 30033047
[TBL] [Abstract][Full Text] [Related]
24. Whole genome methylation sequencing reveals epigenetic landscape and abnormal expression of FABP5 in extramammary Paget's disease.
Kang Z; Jiang L; Chen D; Yan G; Zhang G; Lai Y; Zeng Q; Wang X
Skin Res Technol; 2023 Oct; 29(10):e13497. PubMed ID: 37881057
[TBL] [Abstract][Full Text] [Related]
25. Serum cell-free DNA levels are a useful marker for extramammary Paget disease.
Mijiddorj T; Kajihara I; Tasaki Y; Otsuka-Maeda S; Sakamoto R; Sawamura S; Kanazawa-Yamada S; Egashira S; Inoue K; Makino K; Miyashita A; Aoi J; Igata T; Makino T; Masuguchi S; Fukushima S; Jinnin M; Morinaga J; Ikeda T; Ihn H
Br J Dermatol; 2019 Sep; 181(3):505-511. PubMed ID: 30706452
[TBL] [Abstract][Full Text] [Related]
26. Detection of ERBB2 Amplification by Next-Generation Sequencing Predicts HER2 Expression in Colorectal Carcinoma.
Cenaj O; Ligon AH; Hornick JL; Sholl LM
Am J Clin Pathol; 2019 Jun; 152(1):97-108. PubMed ID: 31115453
[TBL] [Abstract][Full Text] [Related]
27. Genomic
Li M; Liu F; Zhang F; Zhou W; Jiang X; Yang Y; Qu K; Wang Y; Ma Q; Wang T; Bai L; Wang Z; Song X; Zhu Y; Yuan R; Gao Y; Liu Y; Jin Y; Li H; Xiang S; Ye Y; Zhang Y; Jiang L; Hu Y; Hao Y; Lu W; Chen S; Gu J; Zhou J; Gong W; Zhang Y; Wang X; Liu X; Liu C; Liu H; Liu Y; Liu Y
Gut; 2019 Jun; 68(6):1024-1033. PubMed ID: 29954840
[TBL] [Abstract][Full Text] [Related]
28. Precise ERBB2 copy number assessment in breast cancer by means of molecular inversion probe array analysis.
Christgen M; van Luttikhuizen JL; Raap M; Braubach P; Schmidt L; Jonigk D; Feuerhake F; Lehmann U; Schlegelberger B; Kreipe HH; Steinemann D
Oncotarget; 2016 Dec; 7(50):82733-82740. PubMed ID: 27716627
[TBL] [Abstract][Full Text] [Related]
29. Treatment of metastatic extramammary Paget's disease associated with adnexal adenocarcinoma, with anti-HER2 drugs based on genomic alteration ERBB2 S310F.
Vornicova O; Hershkovitz D; Yablonski-Peretz T; Ben-Itzhak O; Keidar Z; Bar-Sela G
Oncologist; 2014 Sep; 19(9):1006-7. PubMed ID: 25085898
[TBL] [Abstract][Full Text] [Related]
30. Lymphovascular and marginal invasion as useful prognostic indicators and the role of c-erbB-2 in patients with male extramammary Paget's disease: a study of 31 patients.
Choi YD; Cho NH; Park YS; Cho SH; Lee G; Park K
J Urol; 2005 Aug; 174(2):561-5. PubMed ID: 16006892
[TBL] [Abstract][Full Text] [Related]
31. Clinicopathological factors associated with HER2 status in gastric cancer: results from a prospective multicenter observational cohort study in a Japanese population (JFMC44-1101).
Matsusaka S; Nashimoto A; Nishikawa K; Miki A; Miwa H; Yamaguchi K; Yoshikawa T; Ochiai A; Morita S; Sano T; Kodera Y; Kakeji Y; Sakamoto J; Saji S; Yoshida K
Gastric Cancer; 2016 Jul; 19(3):839-51. PubMed ID: 26265390
[TBL] [Abstract][Full Text] [Related]
32. Targeted next-generation sequencing enables reliable detection of HER2 (ERBB2) status in breast cancer and provides ancillary information of clinical relevance.
Pfarr N; Penzel R; Endris V; Lier C; Flechtenmacher C; Volckmar AL; Kirchner M; Budczies J; Leichsenring J; Herpel E; Noske A; Weichert W; Schneeweiss A; Schirmacher P; Sinn HP; Stenzinger A
Genes Chromosomes Cancer; 2017 Apr; 56(4):255-265. PubMed ID: 27792260
[TBL] [Abstract][Full Text] [Related]
33. Gene amplification of CCNE1, CCND1, and CDK6 in gastric cancers detected by multiplex ligation-dependent probe amplification and fluorescence in situ hybridization.
Ooi A; Oyama T; Nakamura R; Tajiri R; Ikeda H; Fushida S; Dobashi Y
Hum Pathol; 2017 Mar; 61():58-67. PubMed ID: 27864121
[TBL] [Abstract][Full Text] [Related]
34. Relapsed classic E-cadherin (CDH1)-mutated invasive lobular breast cancer shows a high frequency of HER2 (ERBB2) gene mutations.
Ross JS; Wang K; Sheehan CE; Boguniewicz AB; Otto G; Downing SR; Sun J; He J; Curran JA; Ali S; Yelensky R; Lipson D; Palmer G; Miller VA; Stephens PJ
Clin Cancer Res; 2013 May; 19(10):2668-76. PubMed ID: 23575477
[TBL] [Abstract][Full Text] [Related]
35. erbB-2 overexpression but no activation of beta-Catenin gene in extramammary Paget's disease.
Takata M; Fujimoto A; Aoki H; Hatta N; Ooi A; Takehara K
J Invest Dermatol; 1999 Aug; 113(2):258-62. PubMed ID: 10469313
[TBL] [Abstract][Full Text] [Related]
36. PIG7/LITAF gene mutation and overexpression of its gene product in extramammary Paget's disease.
Matsumura Y; Matsumura Y; Nishigori C; Horio T; Miyachi Y
Int J Cancer; 2004 Aug; 111(2):218-23. PubMed ID: 15197774
[TBL] [Abstract][Full Text] [Related]
37. Plasma HER2 (
Siravegna G; Sartore-Bianchi A; Nagy RJ; Raghav K; Odegaard JI; Lanman RB; Trusolino L; Marsoni S; Siena S; Bardelli A
Clin Cancer Res; 2019 May; 25(10):3046-3053. PubMed ID: 30808777
[TBL] [Abstract][Full Text] [Related]
38. miR-31 is distinctively overexpressed in primary male extramammary Paget's disease.
Guo H; Qi RQ; Lv YN; Wang HX; Hong YX; Zheng S; Li JH; Gao XH; Chen HD
Oncotarget; 2016 Apr; 7(17):24559-63. PubMed ID: 27016415
[TBL] [Abstract][Full Text] [Related]
39. Frequent amplifications of ESR1, ERBB2 and MDM4 in primary invasive lobular breast carcinoma.
Cao L; Basudan A; Sikora MJ; Bahreini A; Tasdemir N; Levine KM; Jankowitz RC; McAuliffe PF; Dabbs D; Haupt S; Haupt Y; Lucas PC; Lee AV; Oesterreich S; Atkinson JM
Cancer Lett; 2019 Oct; 461():21-30. PubMed ID: 31229512
[TBL] [Abstract][Full Text] [Related]
40. Somatic alterations of TP53, ERBB2, PIK3CA and CCND1 are associated with chemosensitivity for breast cancers.
Yang L; Ye F; Bao L; Zhou X; Wang Z; Hu P; Ouyang N; Li X; Shi Y; Chen G; Xia P; Chui M; Li W; Jia Y; Liu Y; Liu J; Ye J; Zhang Z; Bu H
Cancer Sci; 2019 Apr; 110(4):1389-1400. PubMed ID: 30776175
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
